ArticleDiabetology international2025
Association between serum neopterin level and diabetic peripheral neuropathy in patients with type 2 diabetes: a pilot observational study.
Article in Diabetology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic peripheral neuropathy (DPN) is a prevalent and disabling complication of type 2 diabetes mellitus (T2D), leading to significant morbidity and reduced quality of life. Chronic hyperglycemia, metabolic disturbances, and immune system activation are contributors to the development and evolution of DPN. Neopterin, a pteridine derivative produced by activated macrophages, reflects cellular immune activation and oxidative stress, both of which are implicated in diabetic complications. However, the role of serum neopterin as a potential biomarker for diabetic neuropathy has not been fully elucidated. This study aimed to investigate the association between serum neopterin levels and diabetic peripheral neuropathy in patients with T2D. Methods: A total of 90 participants were enrolled, including 60 patients with T2D and 30 age- and sex-matched healthy controls. The T2D group was subdivided into 30 patients with DPN and 30 patients without DPN. Serum neopterin levels were measured using ELISA. All participants underwent nerve conduction studies (NCS) and Toronto clinical neuropathy score (TCNS) assessments. Glycemic and lipid profiles were also analyzed. Results: Serum neopterin levels were significantly elevated in T2D patients with DPN compared to those without neuropathy and healthy controls. Higher neopterin levels were strongly associated with neuropathy severity, as patients with axonal neuropathy exhibited the highest neopterin concentrations. Additionally, neopterin correlated positively with TCNS scores, NCS results, and altered lipid profile, suggesting a link between metabolic dysregulation and immune activation in DPN. Conclusion: Elevated serum neopterin levels may reflect underlying immune activation and oxidative stress in T2D patients with DPN. Neopterin could function as a valuable biomarker for the early detection and severity assessment of DPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.